This update is based on a press release statement from Marker Therapeutics (NASDAQ:MRKR), with the data cutoff for the APOLLO study being September 10, 2024. The company continues to focus on operational excellence and the advancement of its T cell-based immunotherapies to improve patient outcomes. With impressive revenue growth of 79% in the last twelve months, investors seeking deeper insights into Marker Therapeutics' potential can access additional analysis and 8 more key ProTips through InvestingPro's comprehensive financial toolkit. With impressive revenue growth of 79% in the last twelve months, investors seeking deeper insights into Marker Therapeutics' potential can access additional analysis and 8 more key ProTips through InvestingPro's comprehensive financial toolkit. The study, which included nine patients from five U.S. clinical sites, reported a 78% objective response rate with 44.4% achieving complete response at first assessment.
This update is based on a press release statement from Marker Therapeutics, with the data cutoff for the APOLLO study being September 10, 2024. The company continues to focus on operational excellence and the advancement of its T cell-based immunotherapies to improve patient outcomes. With impressive revenue growth of 79% in the last twelve months, investors seeking deeper insights into Marker Therapeutics' potential can access additional analysis and 8 more key ProTips through InvestingPro's comprehensive financial toolkit.
Long-term follow-up data, ranging from 6 to 12 months, is available for three patients, with ongoing assessments to monitor the durability of responses. The company aims to enroll additional participants to further validate the safety and effectiveness of the treatment.
MT-601 targets six different tumor antigens found in lymphoma cells and represents a non-genetically modified approach to T cell therapy. This method is designed to reduce the risk of mutagenesis and is potentially easier and less expensive to manufacture compared to current engineered T cell therapies.
The need for alternative treatments is significant as 40-60% of patients relapse within the first year after receiving CD19-targeting CAR-T cell therapies. The current lack of approved standard care for post-CD19 CAR-T relapsed patients highlights the urgency for new therapies.
Marker Therapeutics' President and CEO, Juan Vera, M.D., expressed optimism about MT-601's potential to meet this unmet medical need. The company will continue to treat participants and gather comprehensive data to guide the development of MT-601 for patients with lymphoma.
This update is based on a press release statement from Marker Therapeutics, with the data cutoff for the APOLLO study being September 10, 2024. The company continues to focus on operational excellence and the advancement of its T cell-based immunotherapies to improve patient outcomes.
In other recent news, Marker Therapeutics, a clinical-stage immuno-oncology company, has received a substantial grant of $9.5 million from the Cancer Prevention & Research Institute of Texas (CPRIT). This funding will be utilized for a clinical study of their immunotherapy product, MT-601, specifically for metastatic pancreatic cancer patients. The grant, along with a $2 million award from the NIH Small Business Innovation Research (SBIR) program, is set to propel MT-601's clinical program, which is anticipated to begin in 2025.
MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, is also being examined in a separate study for CD19-CAR relapsed lymphoma. The product targets six tumor-specific antigens highly expressed in various cancers and has shown promising preliminary results in a study at City of Hope National Medical (TASE:PMCN) Center.
In addition to these developments, Marker Therapeutics has demonstrated impressive revenue growth of 79% over the last year. However, analysts do not expect the company to reach profitability this year. These recent developments emphasize Marker Therapeutics' commitment to advancing T cell-based immunotherapies, aiming to improve patient outcomes through innovative treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.